Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis
D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience
D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
D2.366 - The establishment of a Japanese cypress pollen environmental exposure chamber protocol
D2.367 - Omalizumab Efficacy in Relapse of Nasal Polyposis
D2.368 - Lack of anaerobic gut bacteria in patients with aspirin intolerance and allergy
D2.369 - Impaired Retinoic Acid Metabolism and Eotaxin Overexpression in Eosinophilic Chronic Rhinosinusitis: Insights into Pathophysiology and Therapeutic Potential of CRABP1 Targeting
D2.370 - Trends in Sensitization to Pet Allergens and Correlation between Symptoms and Asthma in Allergic Rhinitis from 2017 to 2023 in China
D2.372 - Evaluating ChatGPT's Performance in Answering Questions About Allergic Rhinitis and Chronic Rhinosinusitis
D2.374 - Smoking increases mortality risk of chronic inflammatory airway diseases: a real-world hospital cohort study
D2.375 - Concomitant allergic and ENT pathology in children with chronic inflammatory diseases
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download